Abstract. T-cell receptor engagement by peptide/MHC complexes constitutes the main signal for the activation of naive T cells, but for a productive generation and maintenance of effector cells, full activation requires additional signals driven by costimulatory molecules present on activated antigenpresenting cells. Herein we describe T cell costimulation via CD25, the interleukin (IL)-2 receptor, during priming of naive T cells with a tumor vaccine. To this end, we produced, purified and characterized the fusion protein bsHN-IL2 which contains the IL-2 cytokine and an antibody scFv fragment directed towards the Hemagglutinin-Neuraminidase (HN) protein of Newcastle Disease Virus (NDV). Tumor vaccine cells were modified by infection with this virus which allows the attachment of the immunocytokine bsHN-IL2. In the presence of CD3-mediated signal 1, the vaccine/bsHN-IL2 provided via CD25 a strong bystander antitumor effect in vitro leading to tumor growth inhibition, even stronger than the vaccine/bsHN-CD28 which provides costimulation via CD28. Transcriptome analysis of naive T cells which were stimulated with the vaccine/bsHN-IL2 showed, similarly to the vaccine/ bsHN-CD28, upregulation of 71 genes belonging to different signalling pathways, including PLC-Á1, Grb-2, Vav-1 and PDE-4A. Analysis of the supernatants of activated T cells with ligand-bound tumor vaccine showed that the vaccine/ bsHN-IL2, in contrast to the vaccine/bsHN-CD28, did not lead to the production of additional IL-2. We report here the first transcriptome analysis of IL-2 receptor mediated costimulatory signals. The findings provide new insights into mechanisms of function of IL-2 during T cell priming.
Introduction
It is well accepted that the key players in protective anti-cancer adaptive immune responses are T lymphocytes. Patients with tumor-specific T cell responses, including those with T cell memory in their bone marrow (1) or those with tumor-infiltrating T lymphocytes (2) apparently have a better prognosis than those without such T cell immune responses. Nevertheless, the T cell responses are often not strong enough to prevent tumor growth. Various tumor inhibitory mechanisms account for this phenomenon, for instance impaired presentation of tumor-associated antigens (TAA) by MHC-I molecules (3, 4) , the lack of costimulatory ligands for T cell activation (5) and the immunosuppressive microenvironment which a growing tumor is building up by secreting suppressive cytokines or by inducing regulatory T (Treg) cells that locally repress anti-tumor T cell attacks (6) (7) (8) . Also, TAA-specific T cells may become anergized in cancer patients. There is thus a need for improved immunotherapeutic approaches to by-pass these problems.
Naive T cells, which represent about 50-80% of the total T cells, have more complex activation requirements compared to antigen experienced memory T cells. For their activation, the recognition of cognate antigen (e.g., MHC: peptide complex) by the TCR which provides signal 1 is not sufficient. Additional signals, called co-stimulatory signals, are required to induce proliferation and effector functions. Under physiological conditions, costimulatory signals are provided by professional antigen presenting cells such as DCs. B7 molecules (B7-1:CD80, B7-2:CD86), which interact with CD28 on T-cells, are the best-characterized costimulatory molecules (9, 10) . Cross-linking of CD28 molecules on T cells in presence of signal 1 leads to the production of IL-2 (11-13), a cytokine pivotal for T cell growth, survival and cytotoxicity (14) . CD28 ligation without cognitive interaction (in the absence of antigen recognition) has no effect on T cells. After activation, T-cells go from G0 into the G1 phase of the cell cycle. Simultaneously or successively, several surface molecules become upregulated, which either enhance or support the activation of effector functions. Activated T cells upregulate, among other molecules, LFA-1 (a heterodimeric integrin binding to ICAM-1 and ICAM-2), CD2 (a ligand for LFA-3) or VLA-4 (·4: ß1 integrin heterodimer, which binds to VCAM-1). Such adhesive molecular interactions strengthen the cognitive interactions between T cells and APCs and lead to improved migration and extravasation of INTERNATIONAL JOURNAL OF ONCOLOGY 37: 1439 -1452 Transcriptome analysis and cytokine profiling of naive T cells stimulated by a tumor vaccine via CD3 and CD25
T cells into inflammatory tissues (15, 16) . Furthermore, the production of various cytokines is increased during T cell activation. For example, interleukin-2 (IL-2) and the · chain of the IL-2 receptor (IL-2R) are being induced. The latter consists of three chains: IL-2R· (CD25), IL-2Rß (CD122) and IL-2RÁc (CD132). Resting cells have a form of IL-2 receptor, which consists only of the ß-and Ác-chain. These receptors have only a medium affinity for IL-2. Only through the formation of a trimer with the ·-chain, the receptor has a maximum affinity for its ligand IL-2 (17, 18) . The IL-2 cytokine is important since it influences in an auto-and paracrine fashion the clonal expansion of T-cells (19) .
In this study, we used the tumor selective replication properties of an avian paramyxovirus, the Newcastle Disease Virus (NDV) (20) , to introduce at the surface of tumor cells the viral antigen Hemagglutinin-Neuraminidase (HN). This allows to target immunostimulatory molecules to such infected tumor cells. Human tumor cell infection by NDV was shown to be an efficient and safe way to produce the human cancer vaccine ATV-NDV (for autologous tumor vaccine infected by NDV). It showed pleiotropic immunostimulatory properties (21) and led to upregulation at the cell surface of the HN and F proteins of NDV (22) .
As immunostimulatory molecules, we used 3 different recombinant proteins. The first, the bispecific single-chain antibody bsHN-CD3, provides T cell activation signals by interacting with the TCR-associated CD3 complex (signal 1). The second, the bispecific single-chain antibody bsHN-CD28 provides, via anti-CD28, costimulatory signals (signal 2). The third protein, the immunocytokine bsHN-IL2 introduces with IL-2 a tumor cell surface bound ligand for CD25 [interleukin-2 receptor (IL-2R)] on T cells. These molecules were introduced into the NDV infected vaccine to provide additional signals for T cell activation. Such additional signals may be required in cancer patients whose T cells exhibit a high degree of unresponsiveness to stimulation via TAA or in patients whose tumors do not express TAAs.
In this study, the effects of the fusion protein bsHN-IL2 of the modified vaccine have been analyzed in more detail. We analyzed the transcriptome of naive T cells after their activation, in the presence of suboptimal signal 1, with a tumor vaccine expressing IL-2 at their surface. We compared the stimulation of naive T cells by this vaccine to the one obtained with a vaccine providing a co-stimulatory signal via CD28. We also analysed the cytokine responses of such activated T cells. We will demonstrate that IL-2 immunocytokines, when targeted to NDV-infected tumor cells, and combined with a suboptimal TCR-mediated signal (signal 1; anti-CD3 as a surrogate for TAAs), provide a strong costimulatory signal to purified naive human T lymphocytes. Such IL-2 receptor-mediated costimulatory signals show many similarities but also some differences to 'classical' CD28-mediated costimulatory signals.
Materials and methods
Cell lines and preparation of the tumor vaccine. All cell lines were obtained from the tumor cell bank of the German Cancer Research Center (DKFZ; Heidelberg, Germany). Cell culture media were supplemented with 2 mM L-glutamine, 10 mM HEPES, 100 U/ml penicillin and 100 μg/ml streptomycin (all purchased from Gibco Invitrogen, Karlsruhe, Germany). The human breast carcinoma cell line MCF-7 was cultured in DMEM with 10% fetal calf serum (FCS). The murine fibroblast Ltk-HN transfectant (23) and the Jurkat cell line sorted for CD28 expression (JCD28) was cultured in RPMI-1640 medium with 10% FCS. Human peripheral blood mononuclear cells (PBMC) were isolated via Ficoll-Paque (Amersham Biosciences, Freiburg, Germany) centrifugation from buffy coat or from fresh heparinized blood of healthy donors. Untouched T cells (TCs) were purified with the T Cell Negative Isolation Kit (Dynal, Hamburg, Germany), involving magnetic separation of non-T cells labelled with mouse mAbs against human CD14, CD16a/b, CD56 and HLA-II DR/DP, via Dynabeads coated with human IgG4 against mouse IgG Fc. Naive T cells were purified in a similar way by adding an anti-CD45RO mAb to the above mentioned antibody cocktail to remove also memory T cells.
Tumor vaccine. For the preparation of the vaccine, the avirulent, non-lytic strain Ulster of NDV was used. Origin, maintenance, purification, and quantification have been described (21) . MCF-7 cells were Á-irradiated via a 137 Cs source (Gammacell 1000; Atomic Energy of Canada, Chalk River, Canada), and then modified for 1 h at 37˚C with 100 hemagglutination units (HU) of NDV per 1x10 7 cells (MCF-7-NDV or V), as described (21) .
Recombinant proteins. The bispecific antibodies bsHN-CD3 (no. 242) and bsHN-CD28 (no. 290) (24) as well as bsHN-IL2 (no. 356) (25) have been described. Briefly, the plasmid with the corresponding construct were elaborated using scFv specific for CD3, CD28 and HN of NDV derived respectively from the hybridoma clones TR66, 9.3 and HNB as desbribed in ref. 24 . These plasmid were transfected in CHO cells and stable clones expressing high levels of the desired proteins were cultured in ·MEM containing 5% dialyzed FCS (dFCS; Biochrom, Krefeld, Germany) and 10 nM methotrexate (Calbiochem, Schwalbach, Germany). The production was conducted in high density cell culture systems (Integra Biosciences, Fernwald, Germany). Each protein was then purified and characterized biochemically for our study. The protein concentration was determined with the CB-Protein Assay™ reagent (Calbiochem) and using bovine serum albumin (BSA, Sigma, Schnelldorf, Germany) as reference protein.
Antibodies and flow cytometry. PE-labelled goat F(ab') 2 antimouse IgG was from Southern Biotech (Birmingham, USA). PE-conjugated mAb against murine CD25 and the corresponding PE-conjugated rat IgG1 mAb as negative control were obtained from BD Pharmingen (Heidelberg, Germany). The PE-conjugated anti-CD3, the FITC-conjugated anti-CD4, the APC-conjugated anti-CD25 as well as the FITC-conjugated anti-CD45RA mAbs were purchased from BD Pharmingen. The anti-EpCAM mAb (HEA-125) was a kind gift of Dr G. Moldenhauer (DKFZ). The purified anti-CD45RO, the allophycocyanin (APC)-conjugated anti-CD8, the fluorescein isothiocyanate (FITC)-conjugated anti-CD25 as well as the phycoerythrin (PE)-labelled anti-CD45RO and anti-CD107a mAbs were purchased from Becton-Dickinson (BD) Pharmingen. The secondary antibodies goat F(ab') 2 anti-mouse PE Mouse IgM, IgG, IgA (H+L) and the goat anti-mouse FITC mouse IgG2a (only HÁ2a) were purchased from Southern Biotech, Birmingham (USA) whereas Endobulin (human, intact IgG) from Baxter (Unterschleissheim, Germany) and streptavidin-PE from BD Pharmingen.
For the analysis of human naive T cell activation, ≤1x10 6 T lymphocytes were first blocked with Endobulin (human immunoglobulins, 50 μg/μl; Baxter, Unterschleissheim, Germany), before being stained for flow cytometry. The cell suspensions were analyzed with a FACSCalibur fluorescence analyzer (Becton-Dickinson). In some proliferation assays, T cells were labelled by short incubation with a CFSE solution. Propidium iodide (PI, 0.5 μg/μl; Sigma-Aldrich, Schnelldorf, Germany) was added to all cell suspensions immediately before the FACS analysis to exclude dead cells. The data were analyzed using the FlowJo software (Tree Star, Ashland, USA).
Mixed lymphocyte tumor cell culture (MLTC).
In this assay, 1x10 5 freshly isolated naive T cells per well were co-incubated in 96-well round bottom microtiter plates with 1x10 4 stimulator cells (Ltk-HN cells). After the indicated durations of incubation in presence or absence of the fusion proteins, the cells were harvested, washed and either used in the TNA assay, for array analysis (described below) or stained for FACS analysis (see above).
Tumor neutralization assay (TNA). The assay system was based on (24) with some minor modifications. Briefly, using 96-well plates, 3x10 3 live MCF-7 tumor cells were added to the wells and incubated in culture medium for 4 h until they became adherent. Purified naive T cells that had been preactivated in an MLTC were added to the wells at an effector to tumor cell ratio of 5:1. Then, the indicated amounts of the recombinant proteins were added and incubated until the tumor monolayer in the control wells was confluent.
At the end of the assay, the supernatants of the 96-well TNAs were removed and the wells were carefully washed 5 times with 200 μl RPMI-1640 medium (plus 5% FCS) to remove non-adherent cells. After the last wash, the wells were filled with 100 μl RPMI-1640 medium (plus 5% FCS) and 20 μl MTS solution (MTS Cell Titer 96 ® AQueous; Promega, Mannheim, Germany) was added. The plates were then incubated for 45 min at 37˚C in the dark. When, in the control [tumor monolayer wells [without MLTC)], the colour switched from yellow to brown, the reaction was stopped by adding 20 μl 10% SDS per well. The plates were then evaluated in an ELISA reader at 490 nm. The background was taken from 3 control wells containing only medium, MTS reagent and SDS solution. The percent tumor growth inhibition was calculated as described (24) .
Total RNA extraction and synthesis of labelled cRNA. All kits were purchased from SuperArray (Frederick, USA). After activation of naive T cells for seven days, potentially remaining MCF-7-NDV vaccine cells were removed from the co-cultures by magnetic beads (Dynal, Hamburg, Germany) pre-loaded with an anti-EpCAM mAb. The remaining T cells were lysed and total RNA extracted with the ArrayGrade™ Total RNA Isolation Kit (SuperArray). RNA from freshly isolated naive T cells of the same donor served as reference. Using the TrueLabeling-AMP TM Linear RNA Amplification Kit (SuperArray), the RNA samples were first reverse transcribed into cDNA and then amplified linearly by in vitro transcription into cRNA, a step during which the cRNA was labelled with biotin-16-uridine-5'-triphosphate (biotin-16-UTP, 10 mM; Roche, Mannheim, Germany). Finally, the cRNA samples were purified with the use of the ArrayGrade cRNA Cleanup Kit (SuperArray).
Hybridization onto oligo microarrays and image acquisition.
Gene expression analysis involved the use of customized Oligo DNA Microarrays (SuperArray) containing 247 different human gene probes potentially involved in T cell activation (supplemental data available on request from the authors). Ten microgram of each biotinylated cRNA sample was hybridized overnight at 60˚C to the microarrays, following the manufacturer's instructions (SuperArray). The signals were developed with streptavidin-conjugated alkaline phosphatase and the CDP substrate (Chemiluminescent Detection; SuperArray). The detection was performed with the aid of a cooled CCD camera (Roche, Mannheim, Germany) during an exposure time of 10 min. The images were saved as TIFFformatted 16 bit gray scale images. Data analysis, i.e. quantification of the signal intensities, background correction and normalization with the ribosomal protein S27a (RPS27A) as a house-keeping gene, was carried out with the use of the GEArray Expression Analysis Suite software (v. 1.1; SuperArray). The relative gene expression is given as fold induction in comparison to the reference sample (set as 100%).
Cytokine measurement. The Th1/Th2 response-related cytokines IFN-Á, IL-1ß, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, TNF-· and TNF-ß from supernatants were measured simultaneously by means of a commercially available bead-assisted FACS analysis (Bender MedSystems, Vienna, Austria). IP-10 was quantified by a commercial ELISA (Biosource, Camarillo, USA).
Statistical analysis. Differences between two means were calculated in Excel software with the Student's t-test. They were regarded as statistically significant at p<0.05. As shown in Fig. 2Aa , non-activated T cells form a very compact, homogeneous cell population (long arrow) with small FSC and SSC values whereas the SEB activated T cells (small arrows) differentiated into lymphoblasts, which have a wide variation for both parameters (Fig. 2Aa ). Both proteins, bsHN-CD3 and bsHN-CD28, bound to their respective receptors (CD3 and CD28) on the preactivated T cells as shown by the histograms of Fig. 2Ab and c. BsHN-IL2 also bound to the T cells but there were two binding peaks (Fig. 2Ad) . The middle one corresponds to low affinity binding (CD25 low T cells) and the right to high affinity binding (CD25 high T cells). The expression level of the IL2R· thus appears to correlate with the degree of T cell activation and with binding of bsHN-IL-2.
Results

Binding properties of the recombinant proteins bsHN-CD3, bsHN-IL2 and bsHN-CD28.
Binding of the constructs to CD28 or to the IL-2 receptor was also tested with Jurkat (JCD28) CD28 positive human lymphoma cells and with IL-2 receptor positive murine Eb lymphoma cells, respectively. The cells were first incubated with the recombinant proteins and then stained with mouse anti-His-tag or mouse anti-E-tag followed by PE-labelled goat F(ab') 2 anti-mouse IgG and then analyzed by flow cytometry (data not shown). To test binding to HN, the proteins were successively diluted 1:2 and their binding to Ltk-HN transfectants analyzed. The dilution, at which 50% of the cells were stained, was set as arbitrary value of 10,000 ¨/ml (U/ml) HN-associated activity. The protein bsHN-CD28 (no. 290) showed a binding activity of about 500,000 U/ml which is 2.5-times higher than the activity observed for the protein no. 356 (with 200,000 U/ml). Table I shows the HN specific activity in terms of U/μg protein and also the IL-2 specific activity.
Phenotypic characterisation of the isolated human naive T cells.
The naive T cells which have been freshly isolated and purified were stained directly with fluorescence labelled antibodies for FACS analysis. As shown in Fig. 2Ba , all cells were CD3 and CD45RA positive. They did not express the memory T-cell marker CD45RO, or CD25 ( Fig. 2Bd and e), nor CD107a (Fig. 2Bf) . Regulatory T cells (Treg) were also not present.
Bystander anti-tumor activity induced in naive T cells by IL-2 expressed at the surface of tumor vaccines.
We next evaluated possible bystander anti-tumor activity of T cells activated via IL-2 expressed at the surface of a tumor vaccine. For this purpose, we used the tumor-neutralization assay (TNA) which is basically a mixed lymphocyte tumor cell culture (MLTC) performed on top of an adherent tumor cell monolayer as bystander target (24) . Co-incubation of PBMC for 5-7 days with the modified vaccine cells resulted in the generation of cytotoxic effector function and in the release of a variety of cytokines. During this effector phase, the bystander tumor cells were lysed or their proliferation inhibited. At the end of the assay, the amount of surviving tumor cells was measured irradiated Ltk-HN cells, suboptimal bsHN-CD3 (50 ng/well) and the reported amounts of bsHN-CD28 (black bars) or bsHN-IL2 (white bars). Controls were naive T cells which were incubated only with the vaccine or with the vaccine to which one of the constructs is bound. After six days, the cells were harvested and given to one in a 96-well plate in which MCF-7 cells (2.5x10 4 cells/well) were added 4 h beforehand. After three days of incubation, the tumor viability was quantified as described in Materials and methods. All values were determined in triplicate and are expressed as mean ± standard deviation.
after removal of the non-adherent cells by addition of MTS, a live cell staining reagent. Strong bystander tumor growth inhibition was observed when a suboptimal anti-CD3 signal was combined with bsHN-IL2 or bsHN-CD28 at the surface of the tumor vaccine (data not shown).
Since the TNA assay does not allow to distinguish between steps of T cell activation and effector function, we next tested the generated effector function separately. MLTC cultures were first performed with naive T cells in the absence of tumor monolayers for six days with Ltk-HN stimulator cells and the indicated HN-specific fusion proteins. Upon transfer onto MCF-7 human breast carcinoma cells, the generated effector T cells exerted within three days the tumor growth inhibition shown in Fig. 2C . There was a significantly higher effector activity in cultures in which a costimulus was provided (either via CD28 or via CD25), in the presence of a suboptimal signal 1. The costimulation via CD25 induced an even stronger bystander anti-tumor effect than the costimulation via anti-CD28.
Synergism and cross-talk between costimulatory signals mediated via IL-2 receptor (CD25) and CD28.
To test the relationship between the co-stimulatory signals mediated via CD25 or CD28, we labelled purified naive T cells with CFSE and co-incubated them for 6 days with a tumor vaccine consisting of irradiated and NDV-infected human MCF-7 breast carcinoma cells. All experimental groups then received a suboptimal amount of bsHN-CD3 alone and 3 different doses Table I . Summary of the characteristics of the 2 purified recombinant proteins bsHN-IL2 and bsHN-CD28 used in this study. ----------------------------------------------- 
The protein number refers to the plasmid that codes for the particular protein, the clone number to the well of the 96-well plate from where the clone was isolated. b The 2 recombinant proteins contained specific binding activities for the viral HN surface antigen and for CD3 (not shown) and CD28 (bottom) as single-chains antibodies. The N-and C-terminal Tag sequences, such as Flag tag or His6 were used for purification as well as for detection of the recombinant proteins in Western blot or FACS. The two recombinant proteins are characterized for their specific HN-activity by determinate their titer in flow cytometry. The HN-activity was quantified by titrating the proteins on HN-expressing Ltk mouse fibroblasts followed by FACS analysis. An arbitrary activity of 10,000 U/ml was attributed to a protein dilution which stained 50% of the Ltk-HN cells.
c After determination of their protein concentration by Bradford, a specific activity was calculated.
d Their IL-2 activity was assessed by using the IL-2 dependent cell line CTLL). The plasmids encoding the bispecific constructs bsHN-CD3 (no. 242) and bsHN-CD28 (no. 290) (24) , as well as bsHN-IL-2 (no. 356) (25) have been described previously. Briefly, transfection of the plasmids into CHO cells was carried out by electroporation (Bio-Rad, Munich, Germany). Clones that were stably expressing the desired fusion protein were selected by limiting dilution technique. The production was conducted in high density cell culture systems (Integra Biosciences, Fernwald, Germany). The fusion proteins containing a His6-tag at their C-terminus were purified by immobilized metal affinity chromatography (IMAC), as described (24) . The E-tag containing protein (bsF-CD28) was purified by means of an anti-E-tag immunoaffinity chromatography procedure (Amersham Biosciences, Freiburg, Germany). The purity of the different fractions was assessed by Coomassie staining after separation of the purified proteins on 12.5% SDS-PAGE gels. The size of the molecules was checked by Western blotting. The fractions exhibiting the highest purity and protein amount were pooled, dialyzed against PBS, filtered (0.22 μm) and stored at -80˚C. of bsHN-CD28 or bsHN-IL2 in all possible combinations. We then determined by FACS analysis the percentage of viable dividing cells (cells with reduced CFSE) co-expressing CD25 and CD45RO. Each of the two co-stimuli alone showed dose-dependent T cell activation over three log scales (Fig. 3A) . Fig. 3B shows a synergistic effect (see the arrow) when CD25 and CD28 mediated signals were combined in suboptimal concentrations. The data suggest that deficiencies of anti-CD28 signals can be compensated by IL-2 and vice versa.
Co-stimulatory signalling pathways elucidated via gene expression profiling. Next we performed a transcriptome analysis to compare the signaling molecules induced by the stimulus bsHN-CD28 (signal 2a) and by the stimulus bsHN-IL2 (signal 2b). Specially designed gene chips were loaded with oligonucleotides specific for 247 genes involved in T cell activation (Fig. 4A) . Naive T cells were isolated from 500 ml fresh blood and their purity evaluated by FACS analysis (~100%). The activation was performed in 96-well To enable an accurate analysis of gene expression, a cooperation was set up with the company SuperArray for the development of a gene chip, which contained a total for 247 gene-specific oligonucleotide probes. The genes, which are involved in T-cell activation included the following seven families of genes: signaling molecules and transcription factors, cell adhesion and cytoskeleton, apoptosis regulators, energy metabolism, receptors, a group of chemokines, cytokines, growth factors and ligands and finally proteases. Genes that could not be clearly assigned to these families, was grouped under the name 'others'. A complete list of the genes together with annotations can be found in the annex. (B) Schema representing the procedure followed to analyze the transcriptome of naive T cells after stimulation with the bsHN-IL2 or bsHN-CD28 loaded MCF7 tumor vaccine. Naive T cells were isolated from 500 ml of fresh blood from a healthy donor and their nearly 100% purity confirmed by FACS (see Fig. 2 ). The activation was performed in 96-well plates. As vaccine were used MCF-7 cells which were irradiated and modified with 100 HU NDV and which were loaded with suboptimal bsHN-CD3 (500 pg/well) in the presence of co-stimulatory bsHN-CD28 or bsHN-IL2 (each 84.4 U/well) or only of one of the three constructs. Unloaded vaccine cells served as controls. 1x10 7 freshly isolated naive T cells were added. A part of non-activated T cells was used to purify RNA for the determination of the zero value (24) . The activation cultures were performed over 7 days, at the end of which microscopic differences were visible. The cells were then centrifuged at 250 g, the supernatants carefully removed and stored until their use at -80˚C. In order to avoid potential interference by possibly remaining vaccine cells, the cells mixture were incubated with magnetic particle-mouse IgG, which were coated with the anti-EpCAM mAb (HEA-125). The obtained T cells were lysed and total RNA isolated. The RNA samples were then transcribed into cDNA, which served as a template for the subsequent cRNA synthesis. In the last step, the cRNA was amplified and simultaneously marked by the use of biotin-16-UTP. Before the cRNAs could be used on the gene chip, it was purified on an affinity column. The amounts of RNA were thus quantified and were found to be between 33.8 and 46.2 μg. The units, which were determined photometrically as OD260/OD280 ratio, were observed for all samples to be >2,280 (data not shown). Ten micrograms cRNA of each sample were hybridized overnight at 60˚C on an array according to manufacturer's instructions. The signals during the chemiluminescence reaction were analyzed with an alkaline phosphatase-conjugated streptavidin, the CDP-substrate and a CCD camera with an exposure time of 10 min. The images were stored as 16-bit greyscale images in TIFF format. The analysis of the data, i.e. quantification of the signals, their correction and normalization using the ribosomal protein S27a (RPS27A) gene as house-keeping gene, was carried out automatically by the software GEArray Expression Analysis Suite. All signals were also checked again manually.
plates with the respective vaccine and, after 7 days, RNAs were prepared from the T cells. All RNA samples exhibited high purity, as assessed by measurement of the optical density (OD) at 260 and 280 nm, respectively. It turned out that the amount of RNA from fully activated naive T cells was three to four times greater than that of the controls.
After reverse transcription, the cDNAs were hybridized and analyzed as described in Materials and methods. In T cells activated via anti-CD3 and IL-2 (CD3/IL-2), 71 genes became upregulated (Fig. 5Ab ) while in cells activated via anti-CD3 and anti-CD28 (CD3/CD28), 76 genes became upregulated (Fig. 5Aa) . In both stimulation cultures, two genes (CXCR4 and the transcription factor Fos) became downregulated. These genes, however, were also downregulated in control cultures indicating an effect of the cell culture as such (Fig. 5Ag) . The suboptimal anti-CD3 stimulus alone upregulated 18 genes (Fig. 5Ad) , the anti-CD28 stimulus alone 6 genes (Fig. 5Ae) and IL-2 alone 22 genes (Fig. 5Af) . In T cells stimulated only by the virus-modified tumor vaccine, there were 18 genes upregulated (Fig. 5Ag) . We conclude that in these control cultures, the upregulation was usually less strong than in the fully activated cultures. Fig. 6 shows quantitative results for some selected genes. A comparison of the black bars reveals that many of the 23 selected upregulated genes were similarly affected by stimulus 2b and stimulus 2a. Since the signals are induced via different receptors, namely CD25(IL-2 receptor) and CD28, these findings suggest synergism and cross-talk between the costimulatory pathways.
Different cytokine profiles induced by co-stimulation via anti-CD28 and IL-2.
The experiment on gene expression profiling was complemented by testing the cytokine content of the supernatants of the different cultures (Table II) . Naive T cells activated via CD3 and CD28 produced high amounts of IL-2, IFN-Á and TNF-·, all Th-1 cytokines. They also produced the pro-inflammatory cytokine TNF-ß and the chemokine IP-10. Naive T cells stimulated via CD3/CD25 (using IL-2) also produced increased levels of various cytokines including IFN-Á and IP-10 but they did not contain more IL-2 than cultures that were given bsHN-IL2 alone. . Naive T cells were stimulated with the 7 types of vaccine indicated. A total of seven samples (S1-S7) were analyzed. The total RNA of the reference (zero value) was obtained on day 0 (d0) from unstimulated 1x10 7 purified naïve T cells. The activation was carried out in 96-well plates. Naïve T cells were incubated with 1x10 4 MCF-7 cells which were irradiated and modified with NDV (100 HU/ 10 up to 7 cells). Suboptimal amounts of bsHN-CD3 (500 pg/well) and 84.4 U/well of bsHN-CD28 or bsHN-IL2 were added. Naïve T cells without the vaccine, with only the vaccine, and with one of the proteins served as controls (as mentioned in this table). After seven days of activation (d7), total RNA of the cells was isolated. The samples were compared to the reference gene expression of naive T cells at day 0 without activation. The different vaccines used for T-cell activation were (a) V+CD3+CD28; (b) V+CD3+CD25; (d) V+CD3; (e) V+CD28; (f) V+CD25; and (g) V. In the scatter plots of (c) the two costimuli CD28 and IL-2 are compared to each other in the presence of suboptimal signal 1.
The differences of cytokine profiles between costimulation via CD28 and via CD25 were both quantitative and qualitative. The CD25-mediated stimulus induced an 8-10-fold lower level of cytokines and in strong contrast to the CD28-mediated stimulus did not induce an IL-2 response.
The results presented in this study show that vaccine bound IL-2 can induce costimulatory signals via triggering CD25 of naive T cells. There were many similarities to CD28 mediated co-stimulation but also differences. Since we observed synergism and cross-talk between CD25 and CD28 mediated signals, a vaccine providing both costimulatory signals might be optimal.
Discussion
We demonstrate here that IL-2, expressed as fusion protein (bsHN-IL2) bound to the surface of a virus-modified tumor vaccine is capable of inducing via CD25 a costimulatory signal for T cell activation.
Preliminary evidence for IL-2-mediated costimulation came from experiments showing induction of proliferation and upregulation of CD25 and CD107a. Vaccine cells modified by bsHN-CD3 (for signal 1) and by bsHN-IL2 induced a similar degree of T cell activation as the vaccine cells modified with bsHN-CD3 and bsHN-CD28 (for signal 2). Such activated Figure 6 . Relative expression of selected genes after CD28 and IL-2 triggering of naive T cells. As in Fig. 5 , purified naive T cells were stimulated by Á-irradiated and NDV-infected MCF-7 tumor vaccine cells (MCF-7-NDV) in the presence of a suboptimal dose of signal 1 (500 pg/well of bsHN-CD3). For the induction of costimulation signals, either bsHN-CD28 or bsHN-IL-2 (black bars, 84 U/well each) were used. Negative controls included naive T cells incubated with MCF-7-NDV cells in the presence of either signal 1 (hatched bars, CD3 alone), costimulatory signal (gray bars, CD28 alone or IL-2 alone), or without any construct (grey bars, vaccine alone). The reference sample comprised unstimulated naive T cells (-) whose gene expression levels was set as 100% (white bars). After seven days of co-culture, RNA was extracted from the activated T cells, and the array analysis performed as detailed in Materials and methods. A selection of some of the interesting genes is shown (supplemental data for a complete annotated list of genes available from the authors). The data are representative of two independent experiments. Shown are the relative expression levels of fully stimulated naive T cells (CD3/CD28 and CD3/IL-2) and the controls (only CD3: only CD28, only IL-2 and only vaccine) as compared to the 0-value. Gene name: VAV1, Vav-1; Rac-1, RAC1; MAP2K1, Mek-1; MAP2K2, Mek-2; MAPK6, Erk-3; MAPK9, JNK2; PRKCQ, protein kinase C-ı; PLC-Á1, phospholipase C-Á1; PDE4A, phosphodiesterase 4A; ACTB, ß-actin; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; TRAF1, TNF receptor-associated factor 1; BCL2L1, bcl-xL; ITG-a L , ·L integrin; ITG-a3, integrin ·3; ITG-b2, integrin ß2; IL15R·, IL-15-receptor ·-chain; CXCR3, chemokine (CXC motif) receptor 3; FASL, Fas ligand; IFN-Á, interferon gamma; TNF-·, TNF alpha, LTA, lymphotoxin · (TNF-ß); FOS, Fos.
naive T cells also showed bystander antitumor effects in an in vitro tumor neutralization assay (TNA).
Kufer et al (26) described a similar approach but they did not use IL-2. They obtained comparable results concerning the activation of naive (CD45RA + RO -) T cells by irradiated stimulator cells which were loaded with bispecific singlechain antibodies with anti-CD3 and CD28 ligand specificities. Kufer et al, in contrast to us, did not use a CD28-specific scFv but a B7-containing fusion protein as costimulus. Unlike the B7 protein, the scFv CD28 only binds to CD28, and not to CTLA-4. Since CTLA-4, which is a late activation antigen of T cells, mediates T cell inhibitory signals, stronger and longer-lasting T-cell activation can be expected from the use of our antiCD28 scFv containing fusion proteins.
To define the transcriptome of naive T cells which were stimulated, we performed a gene chip analysis. As the gene chip contained a total of 247 selected genes, this analysis allowed a more detailed analysis about the co-stimulatory pathway of CD25-mediated costimulatory signaling.
The analyzed genes can be divided into two groups: i) genes for signaling proteins and ii) genes for effector proteins. Signaling occurs a few minutes to several hours after the induction. These signaling proteins are regulated mainly by posttranslational modification such as reversible phosphorylation and through association with secondary 'messenger' molecules (27, 28) , so that the incoming signal can be rapidly transmitted. The observation that these so-called early events were still measurable after seven days of culture with stimulator cells, led us to conclude that the cells are under constant stimulation which thereby increases the expression of some key signaling proteins. Among them were phospholipase C-Á1 (PLC-Á1) and protein kinase C-ı (PKC-ı), which are the starting point of the NF-AT and NF-κB signaling pathway. These were increased only in anti-CD3/CD28 or anti-CD3/IL-2-stimulated naive T cells but not under the control conditions. In addition, the IL-2 receptormediated Jak-STAT signaling cascade was also active (either initiated either by bsHN-IL2 or by endogenous and secreted IL-2).
Proximal events that immediately follow TCR engagement include activation of protein kinases and phosphorylation of multiple enzymes involving scaffold and adaptor molecules (29) . The phosphorylation of LAT, a lipid raft-associated adaptor protein, creates docking sites for SH2 domaincontaining proteins thus creating a platform for the recruitment of multiple signalling molecules (30) . Three such multiple signalling molecules were found to be highly upregulated according to gene expression profiling upon T cell costimulation with IL-2 immunocytokine-modified vaccine: PLC-Á1, the adaptor protein Grb-2 and the Rho-family GTPase exchange factor Vav-1. Anti-CD3/CD25 stimulation also strongly upregulated the expression of the phosphodiesterase type 4A (PDE-4A). These and several other signalling molecules were similarly upregulated in anti-CD3/anti-CD28 and anti-CD3/CD25 stimulated T cells. PLC-Á1 recruitment and activation via the LAT-nucleated signalling complex (31) is connected with three signalling pathways which apparently became activated via IL-2-mediated costimulation: i) the MAP kinase (MAPK) pathway, ii) the NF-AT pathway and iii) the NF-κB pathway. In addition to these classical pathways which are also activated via CD28, the IL-2 signalling involves the IL-2 receptor-mediated Jak/STAT pathway (32, 33) . This leads to the phosphorylation of STAT proteins which also translocate to the nucleus. Our results suggest that costimulation via CD25 on CD3-stimulated TCR signalling networks involves enhanced phosphorylation of PLC-Á1/SH2 domain-containing proteins/Grb-2/Vav-1 (34) and their effects on downstream components including MAPKs. Ligation of IL-2 to the heterotrimeric IL-2 receptor activates the Erk type MAPK signalling pathway involving SOS, Ras, Raf, Mek Table II . Cytokine secretion profile of activated naïve T cells. 
Purified naive T cells were activated for seven days as described in Fig. 4 . After seven days of activation, the supernatants were removed, centrifuged for 5 min at 2,600 g and were then analyzed by flow cytometry with the FlowCytomix Multiplex Human Th1/Th2 10plex kit. Only IP-10 was determined by ELISA. All concentrations are given in pg/ml. The data are representative of two independent experiments.
and Erk (17) . Our data suggest for the first time that IL-2 can also lead to the activation of the Sapk type MAPK signalling pathway (35) and to the activation of c-Jun.
IL-2 has an important influence on the MAPK signalling pathway. For T-cells, there are two different MAPK signaling cascades described: either the Erk-type (Erk, extracellular regulated kinase) or the SAPK-type (SAPK, stress-activated protein kinase) (35) . It has been described that the ligation of IL-2 to the heterotrimeric IL-2 receptor can induce via SOS (a nucleotide exchange factor), Ras (a small G-protein), Raf, Mek and Erk the Erk-type signalling pathway (17) . This was found to be true also for bsHN-IL2. In addition, we observed induction of the SAPK-type signaling pathway by IL-2 in our gene chip experiment which has not been described up to now. This pathway is so far only known for CD3/CD28 fully activated T cells and leads to the stimulation of Jnk (36, 37) and also of Jun, which, along with Fos in the Erk signaling pathway, forms the transcription factor AP-1 which is important for activation of T-cells.
Anti-CD3/IL-2 stimulated upregulation of genes for effector proteins including cell adhesion molecules such as LFA-1 and CD2, members of the TNF and TNF receptor superfamilies such as CD27, CD70, CD40 ligand, Fas ligand, TNF-· and TNF-ß as well as the corresponding receptors. Among apoptosis-related genes we saw an upregulation of the anti-apoptotic gene bcl-xL as well as an upregulation of the pro-apoptotic gene caspase 9. The latter, together with the observed upregulation of CTLA-4, might be interpreted as an indication of cellular events occurring seven days after stimulation which are aiming at termination of the response. We furthermore observed, after anti-CD3/IL-2 stimulation, increased levels of IFN-Á and IP-10 and to some extent IL-10 in the supernatants. The gene chip analysis revealed also an upregulation of the receptor for IP-10 (CXCR3), of the IL-12 receptor ·-chain and of the IL-15 receptor ·-chain. These latter changes are often seen in close association with T cell activation in general, with T cell proliferation and with the generation of memory T cells (38) . It is also of interest to mention the upregulation of ß-actin (ACTB) which is required for organisation of the cytoskeleton and the 40-fold upregulation of the metabolic enzyme GAPDH which provides ATP for the increased metabolism of the activated cells.
In general, the gene chip analysis showed that freshly isolated naive T cells in the presence of a suboptimal signal 1 (bsHN-CD3) could become costimulated via CD25. Similar genes were upregulated after seven days as in T cells that were activated in a classical way via anti-CD3 and anti-CD28. Controls, which had been stimulated with signal 1 or signal 2 alone, showed only marginal responses.
One reason for the similarity in the mode of action of IL-2-and CD28-mediated signals could be the tyrosine kinase p56Lck (Lck) which is associated both with the ß chain of IL-2 receptor (32) and with the TCR-associated co-receptors CD4 and CD8 (39) . This would also explain why other costimulatory molecules such as CD2 do not lead to the activation of the SAPK-type pathway (35) .
Since the two costimuli CD28 and IL-2 seem to use similar signaling pathways in the initiation of a T-cell response, it is not surprising that genes coding for effector proteins, were also similarly upregulated. This was the case for adhesion molecules, the TNF and the TNF receptor superfamily and for regulators of apoptosis and of energy metabolism.
The two co-stimulatory signals mediated either via CD28 or via CD25, however, differed in one aspect, the production of IL-2. While naive T cells activated via CD3/CD28 are capable of secreting IL-2 in large quantities, this was not seen with naive T cells activated via CD3/CD25. Through stimulation with bsHN-IL2, the naive T cells were not capable of producing IL-2. Similar observations were made by Yashiro et al (40) who used mAbs against CD5, CD9, CD2, CD44 and CD11a in the presence of a suboptimal anti-CD3 signal. These stimuli induced a proliferation of naive T cells after 48 h comparable to the one induced via CD28. However, in comparison to the T-cell response mediated by CD28 co-stimulation, the T cell responses mediated by other costimulation molecules led to a decrease in viable cell count and to apoptosis induction. These effects were associated with an inability of these T cells to produce IL-2. An additional administration of recombinant IL-2 to the culture medium prevented the induction of apoptosis (40) . Since exogenous IL-2 is present during T-cell stimulation through the construct bsHN-IL2, CD3/CD25-activated naive T cells should be resistant to apoptosis. The anti-apoptotic protein bcl-xL was highly upregulated in such stimulated cells (41) . In addition, propidium iodide-staining of CD3/CD25-stimulated cells never showed in FACS a higher percentage of dead cells as compared to CD3/CD28-stimulated cells (data not shown). Thus, IL-2 apparently has a dual role via CD25: first it acts in conjunction with the CD3 signal as a costimulus (such as CD28) and secondly, in later stages of activation, as a classic, but integral T-cell growth factor, it supports the expansion of the cells and suppresses apoptosis (42) . In this respect, the IL-2 signal seems to be superior to all other non-CD28-costimuli so far described.
One explanation for the differential capacity for IL-2 production of differently activated naive T cells could be the complex structure of the promoter region of the IL-2 gene. This has binding sites for the previously mentioned transcription factors NF-AT, NF-κB and AP-1, and contains CD28RE (CD28 responsive element), a DNA sequence, to which the CD28RC (CD28 responsive complex) binds (43, 44) . CD28RE is a regulatory sequence for the full induction of the IL-2 promoter. It plays a crucial role for specific transcription factors -e.g., specific members of the NF-κB family such as c-Rel. These are recruited after a B7-1/CD28-stimulus, but not after a non-CD28 stimulus (35, 45) . It is possible that a main effect of CD28 costimulation consists in the loosening of the nucleosomal DNA of the promoter/enhancer region of the IL-2 gene by targeted histone acetylation and demethylation of CpG dinucleotides (46) . It would thus be conceivable that, in our analysis, the signaling pathway induced by IL-2 does not lead to the opening of the compact chromatin structure and/or to the binding of essential transcription factor complexes in the promoter/enhancer-region of the IL-2 promoter.
However, it was demonstrated that HN molecules when expressed at the surface of NDV-infected tumor vaccine induce a B7-1/B7-2-independent costimulation effect leading to induction of CD28RC in T lymphocytes (23, 47) . These observations differ from the present results obtained with naive T-cells in so far as Termeer et al (47) and Ertel et al (23) used, in their studies, memory T cells. These cells can be activated, in contrast to naive T cells, even with a much weaker costimulus. It is then possible that the strength of the co-stimulatory signal (mediated by the HN molecules on the surface of the vaccine cells) was sufficient to activate memory T-cells. But the HN-costimulatory signal is probably not sufficient in strength to lead to the activation of naive T cells.
Overall, these data demonstrate that the response of naive T cells leading to IL-2 production is highly complex. Further experiments are needed to identify the exact mechanisms of signal transduction pathways in CD3/CD25-activated naive T cells and to define the nature of transcription factors at the IL-2-locus involved in activation and proliferation of naive and memory T cells.
In Fig. 7 we present the possible signalling pathways and effects induced by the various stimuli. We are focussing on late events since the analysis was performed at day seven after activation. Nine of the genes that were strongly upregulated are shown in red. They belong to the MAP kinase pathway, to the phospholipase C (PLC)-Á1 pathway or to the protein kinase C-ı pathway. Just as anti-CD28, IL-2 via CD25 apparently can function as a costimulus by being able to activate all these three signalling pathways. In addition there is the IL-2 receptor-dependent Jak/STAT pathway. Of particular significance for T cell costimulation are the molecules Vav-1 and Rac-1. They are linked to ß-actin, cytoskeleton reorganisation, cell migration and, in tumor cells, to invasion and metastasis (48, 49) . The figure also summarizes the effects of the upregulated genes on the cells' function. The effects involve apoptosis, cell adhesion, receptors/ligands and cytokines/chemokines. The main difference between costimulation via CD25 and CD28, as highlighted by the arrow in red, concerns the IL-2 response.
Noteworthy is that the activation of naive T cells by our vaccines loaded with bsAbs or immuno-cytokines is Th1 polarized leading to effector funcions such as cytoxicity and IFN-Á production. This can explain the strong bystander antitumor effects observed in the TNA.
In addition, fully activated naive T cells after five to seven days of exposure to the modified tumor vaccines, express the memory T cell marker CD45RO (26) . Thus, our fusion proteins in combination with the tumor vaccine ATV-NDV, are in a position to induce an immunological T cell memory. That is of clinical and therapeutic relevance.
In conclusion, we discovered in this study that during priming of naive T cells with a second generation tumor vaccine, the new IL-2 immunocytokines provided classical T cell costimulatory activity. Stimulation of naive T cells with tumor vaccine exposing anti-CD3 and IL-2 initiated a cascade of molecular events leading to T cell activation, proliferation and cytokine production. Our data demonstrate that IL-2 participates in the activation of naive T cells as costimulus in a similar but also distinct way as compared to CD28. This could be used for potentiation and broadening of the application of the ATV-NDV tumor vaccine which already has shown in various tumor entities (50) promising results in clinical studies.
